SPRY Earnings Ars Pharmaceuticals, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–19 of 19
| Q1 2026 | 2026-03-31 | -0.61 | 2026-05-15 | 10-Q |
| FY 2025 | 2025-12-31 | -1.74 | 2026-03-09 | 10-K |
| Q3 2025 | 2025-09-30 | -1.32 | 2025-11-10 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.80 | 2025-08-13 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.35 | 2026-05-15 | 10-Q |
| FY 2025 | 2024-12-31 | 0.08 | 2026-03-09 | 10-K |
| Q3 2025 | 2024-09-30 | -0.43 | 2025-11-10 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.24 | 2025-08-13 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.11 | 2025-05-14 | 10-Q |
| FY 2024 | 2023-12-31 | -0.57 | 2025-03-20 | 10-K |
| Q3 2024 | 2023-09-30 | -0.50 | 2024-11-13 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.34 | 2024-08-06 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.16 | 2024-05-09 | 10-Q |
| FY 2023 | 2022-12-31 | -0.87 | 2024-03-21 | 10-K |
| Q3 2023 | 2022-09-30 | -0.66 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.45 | 2023-08-10 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.24 | 2023-05-15 | 10-Q |
| FY 2022 | 2021-12-31 | -0.70 | 2023-03-23 | 10-K |
| Q3 2022 | 2021-09-30 | -1.89 | 2022-11-02 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.